

• **Name:** Seok Jin Kim

• **Current Position:**

Professor, Division of Hematology-Oncology, Department of Medicine  
Samsung Medical Center, Sungkyunkwan University School of Medicine  
81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea

• **Country:** Korea

• **Educational Background:**

1997. 9 – 2003. 2 Ph.D., Graduate School of Korea University, Seoul, Korea

1995. 9 – 1997. 8 Master's degree, Graduate School of Korea University,  
Seoul, Korea

1988. 3 – 1994. 2 Bachelor's degree, College of Medicine, Korea  
University, Seoul, Korea

• **Professional Experiences:**

2014. 4 - Professor, Department of Medicine, Samsung Medical  
Center, Sungkyunkwan University School of Medicine,  
Seoul, Korea

2008. 2 – 2014. 3 Associate professor, Department of Medicine, Samsung  
Medical Center, Sungkyunkwan University School of  
Medicine, Seoul, Korea

2004. 9 – 2008. 1 Assistant professor, Department of Internal Medicine,  
Korea University Anam Hospital, Seoul, Korea

2003. 5 – 2004. 8 Postdoctoral fellow, Medicine-Oncology, Duke  
University Medical Center, NC, USA

2002. 4 – 2003. 4 Fellowship of Hematology/Oncology, Korea University  
Medical Center, Seoul, Korea

1999. 4 – 2002. 3 Officer in Army of Obligation

1995. 3 – 1999. 2 Residency of Internal medicine, Korea University  
Anam Hospital, Seoul, Korea

1994. 3 – 1995. 2 Intern, Korea University Guro Hospital, Seoul, Korea

• **Professional Organizations:**

---

Korean Association of Internal Medicine, Korean Cancer Association  
Korean Society of Hematology, American Society of Hematology  
Korean Society of Blood and Marrow Transplantation

• **Main Scientific Publications:**

**A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.**

**Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS**

**Lancet Oncology 2016 Mar; 17(3): 389-400.**

**A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.**

**Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS**

**Ann Oncology 2016 Apr; 27 (4): 712-8.**

**Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.**

**Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS**

**Ann Oncology 2016 Mar; 27 (3): 508-13.**

**Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.**

**Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Jung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS; Asia Lymphoma Study Group**

**Lancet Haematology 2015 Feb; 2 (2): e66-74.**

**A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic**

**T cell lymphoma.**

Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, Kim J, **Kim SJ**, Kim WS, Lee S, Ko YH

**Nature Genetics 2014 Apr; 46 (4): 371-5.**

**Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone.**

**Kim SJ**, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS

**Blood 2011 Feb 10; 117 (6): 1958-65.**

**Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: Results from a prospective multicenter phase II study.**

**Kim SJ**, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH

**Haematologica 2010 Nov; 95 (11): 1935-42.**

**When do we need central nervous system prophylaxis in the patients with extranodal NK/T cell lymphoma, nasal type?**

**Kim SJ**, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS

**Ann Oncology 2010 May; 21 (5): 1058-63.**

**Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed stage IE/IIIE nasal extranodal NK/T cell lymphoma: CISL study**

**Kim SJ**, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS

**Journal of Clinical Oncology 2009 Dec 10; 27 (35): 6027-6032**